CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 129 filers reported holding CYTOMX THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,014 | -25.0% | 24,817 | 0.0% | 0.00% | – |
| Q2 2023 | $42,685 | +13.9% | 24,817 | 0.0% | 0.00% | – |
| Q1 2023 | $37,474 | -44.5% | 24,817 | -41.2% | 0.00% | – |
| Q4 2022 | $67,554 | +9.0% | 42,221 | 0.0% | 0.00% | – |
| Q3 2022 | $62,000 | -86.1% | 42,221 | -74.7% | 0.00% | – |
| Q1 2022 | $447,000 | -37.1% | 167,178 | +1.9% | 0.00% | – |
| Q4 2021 | $711,000 | -15.1% | 164,014 | -0.1% | 0.00% | – |
| Q3 2021 | $837,000 | -74.1% | 164,258 | -67.8% | 0.00% | -100.0% |
| Q2 2021 | $3,228,000 | -15.4% | 509,929 | +3.3% | 0.00% | 0.0% |
| Q1 2021 | $3,815,000 | +64.2% | 493,509 | +39.2% | 0.00% | 0.0% |
| Q4 2020 | $2,323,000 | +8.0% | 354,643 | +9.7% | 0.00% | 0.0% |
| Q3 2020 | $2,150,000 | -21.2% | 323,242 | -1.3% | 0.00% | 0.0% |
| Q2 2020 | $2,728,000 | +25.5% | 327,404 | +15.6% | 0.00% | 0.0% |
| Q1 2020 | $2,174,000 | +2.4% | 283,323 | +10.9% | 0.00% | 0.0% |
| Q4 2019 | $2,124,000 | +5.6% | 255,479 | -6.3% | 0.00% | 0.0% |
| Q3 2019 | $2,012,000 | -32.1% | 272,582 | +3.2% | 0.00% | -50.0% |
| Q2 2019 | $2,963,000 | -8.8% | 264,071 | -12.6% | 0.00% | 0.0% |
| Q1 2019 | $3,250,000 | -27.5% | 302,299 | +1.8% | 0.00% | -33.3% |
| Q4 2018 | $4,485,000 | -22.4% | 296,965 | -4.9% | 0.00% | -25.0% |
| Q3 2018 | $5,780,000 | +7.2% | 312,419 | +32.4% | 0.00% | 0.0% |
| Q2 2018 | $5,394,000 | -4.4% | 235,926 | +18.9% | 0.00% | 0.0% |
| Q1 2018 | $5,644,000 | +51.5% | 198,366 | +12.4% | 0.00% | +33.3% |
| Q4 2017 | $3,726,000 | +21.9% | 176,502 | +4.9% | 0.00% | 0.0% |
| Q3 2017 | $3,057,000 | +67.6% | 168,223 | +43.0% | 0.00% | +50.0% |
| Q2 2017 | $1,824,000 | +5.5% | 117,642 | +17.5% | 0.00% | 0.0% |
| Q1 2017 | $1,729,000 | +65.3% | 100,091 | +5.2% | 0.00% | +100.0% |
| Q4 2016 | $1,046,000 | -6.3% | 95,132 | +33.7% | 0.00% | 0.0% |
| Q3 2016 | $1,116,000 | +161.4% | 71,166 | +70.6% | 0.00% | 0.0% |
| Q2 2016 | $427,000 | +44.3% | 41,722 | +82.0% | 0.00% | – |
| Q1 2016 | $296,000 | -37.3% | 22,928 | +1.6% | 0.00% | -100.0% |
| Q4 2015 | $472,000 | – | 22,571 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 524,763 | $7,924,000 | 3.84% |
| Congress Park Capital LLC | 123,311 | $1,862,000 | 2.05% |
| Perceptive Advisors | 2,911,715 | $43,588,000 | 1.66% |
| RTW INVESTMENTS, LP | 908,586 | $13,720,000 | 1.28% |
| HAMILTON LANE ADVISORS LLC | 68,753 | $1,038,000 | 0.91% |
| HARBOURVEST PARTNERS LLC | 79,193 | $1,196,000 | 0.57% |
| SPHERA FUNDS MANAGEMENT LTD. | 273,151 | $4,125,000 | 0.46% |
| Exane Asset Management | 50,000 | $755,000,000 | 0.44% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 622,548 | $9,400,000 | 0.38% |
| Cormorant Asset Management, LP | 296,712 | $4,480,000 | 0.36% |